Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

FDA Approves First Gene-Based Test, UroVysion & trade; for Diagnosis of Patients Suspected of Having Bladder Cancer

By Pharmaceutical Processing | March 11, 2005

ABBOTT PARK, IL (Jan. 25, 2005) — The U.S. Food and Drug Administration has approved Abbott’s UroVysion DNA probe assay for use as an aid in the initial diagnosis of bladder cancer in patients with hematuria (blood in urine) suspected of having bladder cancer. With this approval, UroVysion represents the first gene-based test available for bothdiagnosis and monitoring of bladder cancer recurrence.The test is designed to detect genetic changes in bladder cells in urine specimens using a proprietary technology known as fluorescence in situ hybridization or FISH.”UroVysion is significantly more sensitive than conventional methods for the detection of bladder cancer,” said Michael Sarosdy, M.D., of San Antonio, Texas, a urologic oncologist and lead investigator of the UroVysion study.”This new use should allow physicians to make an earlier diagnosis, with earlier treatment,” Dr. Sarosdy said.The FDA based its approval on a Premarket Approval Application (PMA) filed by Abbott in December 2003. Included in that filing were the results of a 23-site study of 497 patients presenting with hematuria. Results demonstrated that UroVysion had greater sensitivity than the most commonly used testing method to detect bladder cancer. The study compared UroVysion performed on urine samples to cystoscopy/histology testing methods and demonstrated a clinical sensitivity of 68.6 percent and a clinical specificity of 77.7 percent. Urine cytology was also performed and demonstrated a relative sensitivity of 39.2 percent and a relative specificity of 91.5 percent.”Studies have shown that early and accurate detection of bladder cancer is key as thousands die each year of this disease,” said Mark S. Soloway, M.D., professor, Department of Urology, University of Miami School of Medicine, and a leading bladder cancer expert. “This is an important new tool for cliniciansto fight bladder cancer.”In 2001, the FDA cleared UroVysion for use in conjunction with cystoscopy to monitor patients for the recurrence of bladder cancer. Prior to that, monitoring was done primarily by cystoscopy and urine cytology.”The FDA’s decision is important because it gives physicians a more powerful diagnostic test than current methods alone to detect one of the most common urological cancers,” said Edward Michael, president, Abbott Molecular.”This approval is the most recent example of Abbott’s significant strides against cancer through advanced molecular diagnostics and new treatments to help patients live longer, healthier lives.”

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE